Proton therapy fails to improve survival outcomes in advanced liver cancer trial
A Phase III clinical trial comparing proton and photon radiation therapies in 115 patients with advanced hepatocellular carcinoma found no significant improvement in overall survival or progression-free survival with proton treatment. Though proton therapy resulted in fewer severe adverse events (11% versus 24%), this difference was not statistically significant. Researchers suggest future studies should focus on identifying patient subgroups that might benefit from proton therapy and evaluating quality-of-life improvements rather than survival outcomes.
The NRG-GI003 study enrolled 115 patients with advanced hepatocellular carcinoma in a randomized comparison of two radiation delivery methods. Participants received either concentrated doses over five treatment sessions or lower doses spread across 15 sessions, with stratification based on tumor characteristics and vascular involvement. Researchers tracked survival rates, disease progression, and treatment side effects over a median follow-up period of 20 months.
The trial's design anticipated that proton therapy would substantially outperform conventional photon radiation in extending survival. However, at the interim analysis point where 53 patient deaths had occurred, the data crossed a predetermined threshold indicating the treatment difference was unlikely to emerge with continued follow-up, prompting early trial termination. The findings suggest future research should explore whether specific patient populations or quality-of-life measures might reveal proton therapy's advantages.
These results could reshape radiation oncology practice for advanced liver cancer patients by redirecting resources toward other treatment combinations rather than the more expensive proton delivery systems. Healthcare systems may reassess proton therapy implementation for HCC populations, potentially affecting treatment access and costs. However, the moderate survival rates observed in both groups suggest radiation remains viable for this disease, and investigators may pursue refined approaches targeting particular patient subgroups, ultimately influencing treatment personalization strategies.